Lupin, recently, announced that they have signed an agreement with a Brazil-based Biotechnology company, Biomm SA. As per the agreement the company will get to exclusively distribute and market ‘Pegfilgrastim’ in Brazil.
Under the terms of the agreement, Biomm will distribute and market biosimilar Pegfilgrastim in Brazil. Pegfilgrastim is used to shorten the duration of neutropenia and the occurrence of febrile neutropenia in chemotherapy patients.
Earlier, in June, the firm had announced that the U.S. FDA has accepted the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim) through a filing using the 351(k) pathway.
Speaking about the acceptance of the Biologics License Application by the U.S. FDA in June. The MD of Lupin, Nilesh Gupta then said that “The pegfilgrastim filing is our first biosimilar filing in the U.S. and is a milestone in our research and innovation journey as we continue to focus on delivering unique and affordable solutions to alleviate disease burden.”